Petrey Aaron C, de la Motte Carol A
From the Department of Pathobiology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195.
From the Department of Pathobiology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195.
J Biol Chem. 2016 Nov 18;291(47):24324-24334. doi: 10.1074/jbc.M116.755660. Epub 2016 Sep 27.
Dynamic alterations of the extracellular matrix in response to injury directly modulate inflammation and consequently the promotion and resolution of disease. During inflammation, hyaluronan (HA) is increased at sites of inflammation where it may be covalently modified with the heavy chains (HC) of inter-α-trypsin inhibitor. Deposition of this unique, pathological form of HA (HC-HA) leads to the formation of cable-like structures that promote adhesion of leukocytes. Naive mononuclear leukocytes bind specifically to inflammation-associated HA matrices but do not adhere to HA constitutively expressed under homeostatic conditions. In this study, we have directly investigated a role for the blood-coagulation protease thrombin in regulating the adhesion of monocytic cells to smooth muscle cells producing an inflammatory matrix. Our data demonstrate that the proteolytic activity of thrombin negatively regulates the adhesion of monocytes to an inflammatory HC-HA complex. This effect is independent of protease-activated receptor activation but requires proteolytic activity toward a novel substrate. Components of HC-HA complexes were predicted to contain conserved thrombin-susceptible cleavage sites based on sequence analysis, and heavy chain 1 (HC1) was confirmed to be a substrate of thrombin. Thrombin treatment is sufficient to cleave HC1 associated with either cell-surface HA or serum inter-α-trypsin inhibitor. Furthermore, thrombin treatment of the inflammatory matrix leads to dissolution of HC-HA cable structures and abolishes leukocyte adhesion. These data establish a novel mechanism whereby thrombin cleavage of HC1 regulates the adhesive properties of an inflammatory HA matrix.
细胞外基质对损伤的动态改变直接调节炎症反应,进而影响疾病的进展与转归。在炎症过程中,炎症部位的透明质酸(HA)含量增加,且可能与α-胰蛋白酶抑制剂重链(HC)发生共价修饰。这种独特的病理性HA(HC-HA)沉积会导致形成促进白细胞黏附的索状结构。未成熟的单核白细胞特异性结合与炎症相关的HA基质,但不会黏附在稳态条件下组成性表达的HA上。在本研究中,我们直接探究了凝血蛋白酶凝血酶在调节单核细胞与产生炎症基质的平滑肌细胞黏附中的作用。我们的数据表明,凝血酶的蛋白水解活性负向调节单核细胞与炎症性HC-HA复合物的黏附。这种作用独立于蛋白酶激活受体的激活,但需要对一种新底物具有蛋白水解活性。基于序列分析预测,HC-HA复合物的成分含有保守的凝血酶敏感切割位点,并且重链1(HC1)被证实是凝血酶的底物。凝血酶处理足以切割与细胞表面HA或血清α-胰蛋白酶抑制剂相关的HC1。此外,对炎症基质进行凝血酶处理会导致HC-HA索状结构溶解,并消除白细胞黏附。这些数据建立了一种新机制,即凝血酶对HC1的切割调节炎症性HA基质的黏附特性。